SINOPHARM GROUP Net Income vs. Return On Asset

X2S1 Stock  EUR 13.10  0.20  1.55%   
Considering SINOPHARM GROUP's profitability and operating efficiency indicators, SINOPHARM GROUP 15ON may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess SINOPHARM GROUP's ability to earn profits and add value for shareholders.
For SINOPHARM GROUP profitability analysis, we use financial ratios and fundamental drivers that measure the ability of SINOPHARM GROUP to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well SINOPHARM GROUP 15ON utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between SINOPHARM GROUP's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of SINOPHARM GROUP 15ON over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Please note, there is a significant difference between SINOPHARM GROUP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SINOPHARM GROUP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SINOPHARM GROUP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

SINOPHARM GROUP 15ON Return On Asset vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining SINOPHARM GROUP's current stock value. Our valuation model uses many indicators to compare SINOPHARM GROUP value to that of its competitors to determine the firm's financial worth.
SINOPHARM GROUP 15ON is rated third in net income category among its peers. It is rated below average in return on asset category among its peers . The ratio of Net Income to Return On Asset for SINOPHARM GROUP 15ON is about  216,208,791,209 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SINOPHARM GROUP's earnings, one of the primary drivers of an investment's value.

SINOPHARM Return On Asset vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

SINOPHARM GROUP

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
7.87 B
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

SINOPHARM GROUP

Return On Asset

 = 

Net Income

Total Assets

 = 
0.0364
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

SINOPHARM Return On Asset Comparison

SINOPHARM GROUP is rated fifth in return on asset category among its peers.

SINOPHARM GROUP Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in SINOPHARM GROUP, profitability is also one of the essential criteria for including it into their portfolios because, without profit, SINOPHARM GROUP will eventually generate negative long term returns. The profitability progress is the general direction of SINOPHARM GROUP's change in net profit over the period of time. It can combine multiple indicators of SINOPHARM GROUP, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GROUP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.

SINOPHARM Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on SINOPHARM GROUP. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of SINOPHARM GROUP position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the SINOPHARM GROUP's important profitability drivers and their relationship over time.

Use SINOPHARM GROUP in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SINOPHARM GROUP position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SINOPHARM GROUP will appreciate offsetting losses from the drop in the long position's value.

SINOPHARM GROUP Pair Trading

SINOPHARM GROUP 15ON Pair Trading Analysis

The ability to find closely correlated positions to SINOPHARM GROUP could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SINOPHARM GROUP when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SINOPHARM GROUP - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SINOPHARM GROUP 15ON to buy it.
The correlation of SINOPHARM GROUP is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SINOPHARM GROUP moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SINOPHARM GROUP 15ON moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SINOPHARM GROUP can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your SINOPHARM GROUP position

In addition to having SINOPHARM GROUP in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small & Mid Caps ETFs Thematic Idea Now

Small & Mid Caps ETFs
Small & Mid Caps ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in SINOPHARM Stock

To fully project SINOPHARM GROUP's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of SINOPHARM GROUP 15ON at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include SINOPHARM GROUP's income statement, its balance sheet, and the statement of cash flows.
Potential SINOPHARM GROUP investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although SINOPHARM GROUP investors may work on each financial statement separately, they are all related. The changes in SINOPHARM GROUP's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on SINOPHARM GROUP's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.